0000950170-22-005637.txt : 20220413 0000950170-22-005637.hdr.sgml : 20220413 20220413090055 ACCESSION NUMBER: 0000950170-22-005637 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220413 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events FILED AS OF DATE: 20220413 DATE AS OF CHANGE: 20220413 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Oncternal Therapeutics, Inc. CENTRAL INDEX KEY: 0001260990 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 621715807 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-50549 FILM NUMBER: 22823771 BUSINESS ADDRESS: STREET 1: 12230 EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 434-1113 MAIL ADDRESS: STREET 1: 12230 EL CAMINO REAL STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: GTX INC /DE/ DATE OF NAME CHANGE: 20030822 8-K 1 onct-20220413.htm 8-K 8-K
false000126099000012609902022-04-132022-04-13

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported) April 13, 2022

Oncternal Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

 

000-50549

 

62-1715807

(State or Other Jurisdiction
of Incorporation)

 

(Commission File
Number)

 

(IRS Employer Identification No.)

 

12230 El Camino Real

Suite 300
San Diego, CA 92130

(858) 434-1113

 

 

(Address and zip code; telephone number, including area code, of registrant’s principal executive offices)

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

ONCT

 

The Nasdaq Stock Market, LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

Oncternal Therapeutics, Inc. (“Oncternal”) estimates that its cash and cash equivalents were approximately $82.2 million as of March 31, 2022. This amount is preliminary and is subject to completion of financial closing procedures. As a result, this amount may differ from the amount that will be reflected in Oncternal’s financial statements as of and for the quarter ended March 31, 2022.

 

The information in this Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

 

Item 8.01. Results of Operations and Financial Condition.

On April 13, 2022, Oncternal announced that has deprioritized further development of its ONCT-216 product candidate, including discontinuing enrollment in Oncternal’s multicenter Phase 1/2 clinical trial of ONCT-216 as a single agent and in combination with vincristine in patients with relapsed or refractory Ewing sarcoma. Oncternal plans to reallocate resources primarily to its zilovertamab global registrational Phase 3 study ZILO-301.

 

Oncternal believes that its existing cash and cash equivalents as of March 31, 2022 will be sufficient to fund its projected operating requirements into the third quarter of 2023.

 

Forward-Looking Statements

Oncternal cautions readers that statements contained in this report regarding matters that are not historical facts are forward-looking statements. These statements are based on Oncternal’s current beliefs and expectations. Such forward-looking statements include Oncternal’s estimated cash and cash equivalents as of March 31, 2022, the allocation of its capital resources, and its forecast of the period of time through which Oncternal’s financial resources will be adequate to support its planned operations. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Such risks and uncertainties include, but are not limited to, potential changes in estimated cash and cash equivalents based on the completion of financial closing procedures and release of complete first quarter 2022 results, risks associated with the clinical development and process for obtaining regulatory approval of Oncternal’s product candidates, such as potential delays in the commencement, enrollment and completion of clinical trials, the anticipated use of cash may increase as a result of factors outside of Oncternal’s control, including if the Food and Drug Administration or other regulatory authorities may require Oncternal to generate additional data or conduct additional preclinical studies or clinical trials, or impose other requirements beyond those that Oncternal currently anticipates, and other risks described in Oncternal’s filings with the Securities and Exchange Commission. Oncternal cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Oncternal undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

 

1

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Oncternal Therapeutics, Inc.

 

 

Date: April 13, 2022

By:

/s/ Richard G. Vincent

 

 

 

Name: Richard G. Vincent

 

 

 

Title: Chief Financial Officer

 

 

2

 EX-101.SCH 2 onct-20220413.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 onct-20220413_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Emerging Growth Company Pre-commencement Issuer Tender Offer Entity Address, State or Province Pre-commencement Tender Offer City Area Code Security Exchange Name Document Period End Date Entity Address, Address Line Two Document Type Entity Address, Address Line One Entity Address, Postal Zip Code Entity Registrant Name Entity Address, City or Town Trading Symbol Local Phone Number Security 12b Title Title of 12(b) Security Written Communications Entity Central Index Key Entity Tax Identification Number Entity File Number Cover [Abstract] Soliciting Material Entity Incorporation State Country Code Entity Incorporation, State or Country Code Amendment Flag EX-101.PRE 4 onct-20220413_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
Apr. 13, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 13, 2022
Entity Registrant Name Oncternal Therapeutics, Inc.
Entity Central Index Key 0001260990
Entity Emerging Growth Company false
Entity File Number 000-50549
Entity Incorporation State Country Code DE
Entity Tax Identification Number 62-1715807
Entity Address, Address Line One 12230 El Camino Real
Entity Address, Address Line Two Suite 300
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92130
City Area Code 858
Local Phone Number 434-1113
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol ONCT
Security Exchange Name NASDAQ
XML 6 onct-20220413_htm.xml IDEA: XBRL DOCUMENT 0001260990 2022-04-13 2022-04-13 false 0001260990 8-K 2022-04-13 Oncternal Therapeutics, Inc. DE 000-50549 62-1715807 12230 El Camino Real Suite 300 San Diego CA 92130 858 434-1113 false false false false Common Stock, par value $0.001 per share ONCT NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.oncternal.com/20220413/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports onct-20220413.htm onct-20220413.xsd onct-20220413_lab.xml onct-20220413_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "onct-20220413.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "onct-20220413.htm" ] }, "labelLink": { "local": [ "onct-20220413_lab.xml" ] }, "presentationLink": { "local": [ "onct-20220413_pre.xml" ] }, "schema": { "local": [ "onct-20220413.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "onct", "nsuri": "http://www.oncternal.com/20220413", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "onct-20220413.htm", "contextRef": "C_0eba9775-5893-4f4b-be70-0d4bdd973fc4", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.oncternal.com/20220413/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "onct-20220413.htm", "contextRef": "C_0eba9775-5893-4f4b-be70-0d4bdd973fc4", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.oncternal.com/20220413/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.oncternal.com/20220413/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.oncternal.com/20220413/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.oncternal.com/20220413/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.oncternal.com/20220413/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.oncternal.com/20220413/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.oncternal.com/20220413/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.oncternal.com/20220413/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.oncternal.com/20220413/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.oncternal.com/20220413/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.oncternal.com/20220413/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.oncternal.com/20220413/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.oncternal.com/20220413/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.oncternal.com/20220413/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.oncternal.com/20220413/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.oncternal.com/20220413/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.oncternal.com/20220413/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.oncternal.com/20220413/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.oncternal.com/20220413/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.oncternal.com/20220413/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.oncternal.com/20220413/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.oncternal.com/20220413/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.oncternal.com/20220413/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 13 0000950170-22-005637-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-22-005637-xbrl.zip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